The 60-second version of Evervie Health Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
Nothing stands out as clearly improving on the years of data available.
No clear supporting case emerges from the available numbers.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹176 Cr | ₹8 Cr | ₹27 Cr | ₹90 Cr | -20.1% |
| EBITDA | ₹130 Cr | -₹4 Cr | -₹3 Cr | ₹36 Cr | -34.7% |
| EBITDA Margin | 73.8% | -47.5% | -10.3% | 40.3% | — |
| PAT (Net Profit) | ₹144 Cr | ₹67 Cr | -₹7 Cr | -₹7 Cr | — |
| EPS | ₹5.87 | ₹2.64 | ₹-0.26 | ₹-0.26 | — |
| ROE | 97.1% | 29.2% | -3.0% | -3.1% | — |
| ROCE | 156.6% | 21.4% | -1.5% | 3.9% | — |
| Total Debt | ₹119 Cr | ₹43 Cr | ₹23 Cr | ₹257 Cr | +29.2% |
| Free Cash Flow | ₹327 Cr | -₹2 Cr | ₹19 Cr | -₹52 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| LARSEN & TOUBRO LTD. | 30.1x | 15.2% |
| SIEMENS LTD | 88.8x | 10.5% |
| ABB INDIA LIMITED | 92.6x | 19.1% |
Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation. 5 high-severity red flags sit above this conclusion and should be read first.